ALLO
Allogene Therapeutics Inc
NASDAQ: ALLO · HEALTHCARE · BIOTECHNOLOGY
$1.78
+1.14% today
Updated 2026-09-11
Market cap
$608.06M
P/E ratio
—
P/S ratio
131.05x
EPS (TTM)
$-0.66
Dividend yield
—
52W range
$1 – $4
Volume
6.1M
Allogene Therapeutics Inc (ALLO) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-44.65M | $-44.65M | $-137.35M | $-115.09M | $-184.81M | $-220.52M | $-237.73M | $-200.30M | $-149.25M |
| Capital expenditures | $5.33M | $3.23M | $50.79M | $65.96M | $21.45M | $5.19M | $1.52M | $694000.00 | $386000.00 |
| Depreciation | — | — | — | — | — | — | — | — | — |
| Stock-based comp | — | $18.57M | $46.06M | $65.26M | $80.82M | $83.60M | $65.95M | $51.74M | $37.64M |
| Free cash flow | $-49.98M | $-47.89M | $-188.14M | $-181.05M | $-206.26M | $-225.71M | $-239.25M | $-200.99M | $-149.63M |
| Investing cash flow | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | $93.73M | $85.69M | $13.38M | $-9.19M | — | — | — | — |
Frequently asked questions
What is Allogene Therapeutics Inc's revenue?
Allogene Therapeutics Inc's trailing twelve-month revenue is $4.64M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How much free cash flow does ALLO generate?
ALLO produced $-149.63M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is ALLO's balance sheet healthy?
ALLO holds $51.69M in cash and equivalents against — in long-term debt, on $292.54M of shareholder equity. That debt is best read against the cash flow the business throws off each year.